Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134511 · ClinicalTrials.gov registry record · Phase 3
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00134511 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 30 participants.
The verdict
NCT00134511, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known disorder of extremely high cholesterol
Interventions
- DRUG Torcetrapib/atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00134511
The ClinicalTrials.gov registry entry for NCT00134511 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Torcetrapib/atorvastatin is the first listed.
NCT00134511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00134511 about?
NCT00134511 is a clinical study titled "Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder". The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known disorder of extremely high cholesterol
What is the current status of trial NCT00134511?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2005-03. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00134511?
The interventions under investigation include: Torcetrapib/atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00134511?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.